Document Detail


Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?
MedLine Citation:
PMID:  20543713     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The role of alpha-1 adrenoceptor antagonists (alpha-blockers) in the management of hypertension continues to evolve. Recent data support their use as add-on therapy in uncontrolled hypertension when used in combination with all other major classes of antihypertensive drug and there is increasing evidence suggesting that they have modest but significant beneficial effects on lipid and glucose metabolism. The availability of extended-release formulations has contributed to an excellent tolerability profile. New data from an observational analysis of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) suggest that doxazosin gastrointestinal therapeutic system (GITS) used as a third-line antihypertensive agent lowered blood pressure and caused modest reductions in plasma lipids. Furthermore, use of doxazosin in ASCOT was not associated with an increased risk of heart failure, in contrast to the earlier finding of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Overall, currently available data support the use of alpha-blockers as safe, well tolerated and effective add-on antihypertensive drugs, which have additional favourable metabolic effects.
Authors:
Neil Chapman; Chung-Yin Chen; Toshiro Fujita; F D Richard Hobbs; Soo-Joong Kim; Jan A Staessen; Supachai Tanomsup; Ji-Guang Wang; Bryan Williams
Related Documents :
2469893 - Alpha 1-adrenoceptor responsiveness: the influence of age.
1283583 - Cardiac hypertrophy and aortic compliance after calcium channel antagonism in hypertens...
11081763 - Therapeutic studies and arterial stiffness in hypertension: recommendations of the euro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of hypertension     Volume:  28     ISSN:  1473-5598     ISO Abbreviation:  J. Hypertens.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-11     Completed Date:  2010-12-07     Revised Date:  2010-12-10    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  1796-803     Citation Subset:  IM    
Affiliation:
International Centre for Circulatory Health, Imperial College, London, UK. neil.chapman@imperial.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-1 Receptor Antagonists / administration & dosage,  adverse effects,  therapeutic use
Antihypertensive Agents / administration & dosage,  adverse effects,  therapeutic use*
Blood Pressure / drug effects
Clinical Trials as Topic
Doxazosin / administration & dosage,  adverse effects,  therapeutic use
Drug Therapy, Combination
Heart Failure / etiology
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Lipids / blood
Myocardial Infarction / prevention & control
Practice Guidelines as Topic
Chemical
Reg. No./Substance:
0/Adrenergic alpha-1 Receptor Antagonists; 0/Antihypertensive Agents; 0/Lipids; 74191-85-8/Doxazosin
Comments/Corrections
Erratum In:
J Hypertens. 2010 Nov;28(11):2351

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabeti...
Next Document:  A new approach to assessing the structural total peripheral resistance amplifier in renal (Page) hyp...